Replies to post #83467 on Biotech Values

[DewDiligence]

VVUS JNJ:

…a deal to avoid litigation makes more sense, like rkrw noted and you probably meant.

I meant more than that—I was responding to north40000’s claim in #msg-41353164 that JNJ could seek an injunction against VVUS to keep Qnexa off the market, which makes no sense. A request by JNJ for an injunction would be rejected because Topamax has already gone generic and hence JNJ cannot plausibly argue that it would be materially harmed by a Qnexa launch.